Proteasome inhibition in hematologic malignancies

Annals of Medicine

Volumn 36, Issue 4, 2004, Pages 304-314

  Richardson, Paul G ^a,b   Hideshima, Teru ^a   Mitsiades, Constantine ^a   Anderson, Kenneth ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Bortezomib; Combined modality therapy; Dexamethasone; Doxorubicin; Leukemia; Lymphoma; Melphalan; Multiple myeloma; non hodgkin; Proteasome inhibition; Thalidomide

Indexed keywords

BORTEZOMIB; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; FLUDARABINE; IDARUBICIN; MELPHALAN; PROTEASOME INHIBITOR; THALIDOMIDE;

ABDOMINAL PAIN; ANEMIA; ANOREXIA; ANXIETY; ARTHRALGIA; ASTHENIA; BACKACHE; BONE PAIN; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CONSTIPATION; COUGHING; DEHYDRATION; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DYSGEUSIA; DYSPEPSIA; DYSPNEA; EDEMA; ENZYME INHIBITION; FATIGUE; FEVER; FOLLICULAR LYMPHOMA; HEADACHE; HERPES ZOSTER; HODGKIN DISEASE; HUMAN; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; INSOMNIA; LARGE CELL LYMPHOMA; LEUKEMIA; MALAISE; MANTLE CELL LYMPHOMA; MULTIPLE MYELOMA; MUSCLE CRAMP; MUSCLE WEAKNESS; MYALGIA; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; PAIN; PARESTHESIA; PERIPHERAL NEUROPATHY; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; RASH; RESPIRATORY TRACT INFECTION; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; VISUAL IMPAIRMENT; VOMITING; WALDENSTROEM MACROGLOBULINEMIA;

ASTHENIA; BORONIC ACIDS; CYSTEINE ENDOPEPTIDASES; DIARRHEA; HEMATOLOGIC NEOPLASMS; HUMANS; MULTIENZYME COMPLEXES; NAUSEA; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 2942706263     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.1080/07853890410030877     Document Type: Review

References (43)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun M. Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26.
2. Rajkumar S, Gertz M, Kyle R, Greipp P, Mayo Clinic Myeloma, Amyloid, and Dysproteinemia Group. Current therapy for multiple myeloma. Mayo Clin Proc 2002;77:813-22.
3. Hussein M. Nontraditional cytotoxic therapies for relapsed/ refractory multiple myeloma. Oncologist 2002;7 (suppl 1):20-9.
4. Adams J. Proteasome inhibition in cancer: development of PS-341. Semin Oncol 2001;28:613-9.
5. Tanaka K, Yoshimura T, Kumatori A, Ichihara A, Ikai A, Nishigai M, et al. Proteasomes (multi-protease complexes) as 20 S ring-shaped particles in a variety of eukaryotic cells. J Biol Chem 1988;263:16209-17.
6. Cobb R, Felts K, Parry G, Mackman N. Proteasome inhibitors block VCAM-1 and ICAM-1 gene expression in endothelial cells without affecting nuclear translocation of nuclear factor-kappa B. Eur J Immunol 1996;26:839-45.
7. Shimbara N, Orino E, Sone S, Ogura T, Takashina M, Shono M, et al. Regulation of gene expression of proteasomes (multi-protease complexes) during growth and differentiation of human hematopoietic cells. J Biol Chem. 1992;267:18100-9.
8. Brandeis M, Hunt T. The proteolysis of mitotic cyclins in mammalian cells persists from the end of mitosis until the onset of S phase. EMBO J 1996;15:5280-9.
9. Clurman B, Sheaff R, Thress K, Groudine M, Roberts J. Turnover of cyclin E by the ubiquitin-proteasome pathway is regulated by cdk2 binding and cyclin phosphorylation. Genes Dev 1996;10:1979-90.
10. An B, Goldfarb R, Siman R, Dou Q. Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ 1998;5:1062-75.
11. Maki C, Huibregtse J, Howley P. In vivo ubiquitination and proteasome-mediated degradation of p53(1). Cancer Res 1996;56:2649-54.
12. Wang C, Mayo M, Korneluk R, Goeddel D, Baldwin A, Jr. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and C-IAP2 to suppress caspase-8 activation. Science 1998;281:1680-3.
13. Conner E, Brand S, Davis J, Laroux F, Palombella V, Fuseler J, et al. Proteasome inhibition attentuates nitric oxide synthase expression, VCAM-1 transcription and the development of chronic colitis. J Pharmacol Exp Ther 1997;282:1615-22.
14. Craiu A, Gaczynska M, Akopian T, Gramm C, Fenteany G, Goldberg A, et al. Lactacystin and clasto-lactacystin b-lactone modify multiple proteasome b-subunits and inhibit intracellular protein degradation and major histocompatibility complex class I antigen presentation. J Biol Chem 1997;272:13437-45.
15. Elliott P, Ross J. The proteasome: a new target for novel drug therapies. Am J Clin Pathol 2001;116:637-46.
16. Adams J, Palombella V, Elliott P. Proteasome inhibition: a new strategy in cancer treatment. Invest New Drugs 2000;18:109-21.
17. Damiano J, Cress A, Hazlehurst L, Shtil A, Dalton W. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 1999;93:1658-67.
18. Chauhan D, Uchiyama H, Urashima M, Yamamoto K, Anderson K. Regulation of interleukin 6 in multiple myeloma and bone marrow stromal cells. Stem Cells 1995;13 (suppl 2):35-9.
19. Mitsiades N, Mitsiades C, Poulaki V, Chauhan D, Fanourakis G, Gu X, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci USA 2002;99:14374-9.
20. Hideshima T, Chauhan D, Schlossman R, Richardson P, Anderson K. The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene 2001;20:4519-27.
21. Almond J, Cohen G. The proteasome: a novel target for cancer chemotherapy. Leukemia 2002;16:433-43.
22. Adams J, Palombella V, Sausville E, Johnson J, Destree A, Lazarus D, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999;59:2615-22.
23. Berenson J, MA H, Vescio R. The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma. Semin Oncol 2001;28:626-33.
24. Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 2002;277:16639-47.
25. Hideshima T, Richardson P, Chauhan D, Palombella V, Elliott P, Adams J, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001;61:3071-6.
26. Anderson K. Targeted therapy to multiple myeloma. Semin Hematol 2001;38:286-94.
27. Mitsiades N, Mitsiades C, Richardson P, Poulaki V, Tai Y, Chauhan D, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003;101:2377-80.
28. Mitsiades N, Mitsiades C, Poulaki V, Chauhan D, Richardson P, Hideshima T, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002;99:4525-30.
29. Mitsiades C, Treon S, Mitsiades N, Shima Y, Richardson P, Schlossman R, et al. TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood 2001;98:795-804.
30. LeBlanc R, Catley L, Hideshima T, Lentzsch S, Mitsiades C, Mitsiades N, et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 2002;62:4996-5000.
31. Orlowski R, Stinchcombe T, Mitchell B, Shea T, Baldwin A, Stahl S, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002;20:4420-7.
32. Aghajanian C, Soignet S, Dizon D, Pien C, Adams J, Elliott P, et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 2002;8:2505-11.
33. Richardson P, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-17.
34. Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol 1998;102:1115-23.
35. Berenson J, Jagannath S, Barlogie B, Siegel D, Alexanian R, Irwin D, et al. Experience with long-term therapy using the proteasome inhibitor, bortezomib, in advanced multiple myeloma (MM). Proc Am Soc Clin Oncol 2003;22:581.
36. VELCADE® (bortezomib) for Injection Prescribing Information. 2003; Cambridge, Mass: Millennium Pharmaceuticals, Inc.
37. Cortes J, Estey E, Giles F, O'Brien S, Keating M, McConkey D, et al. Phase I study of bortezomib (PS-341, VELCADE®), a proteasome inhibitor, in patients with refractory or relapsed acute leukemias and myelodysplastic syndromes. Blood 2002;100:560a.
38. O'Connor O, Wright J, Moskowitz C, Macgregor-Cortelli B, Straus D, Horse-Grant D, et al. Phase II clinical experience with the proteasome inhibitor bortezomib (formerly PS-341) in patients with indolent lymphomas. Proc Am Soc Clin Oncol 2003;22:566.
39. Goy A, East K, Mesina O, Cabanillas F, Fayad L, Hagemeister F, et al. Report of a phase II study of proteasome inhibitor bortezomib in patients with relapsed or refractory indolent aggressive B-cell lymphoma. Proc Am Soc Clin Oncol 2003;22:570.
40. Raza A, Lisak L, Tahir S, Billmeier J, Willmann H, Bellak D, et al. Myelodysplastic syndrome patients show a variety of hematologic responses to proteasome inhibitor bortezomib (PS 341). Blood 2002;100:338b.
41. Orlowski R, Voorhees P, Garcia R, Hall M, Adams J, Esseltine D, et al. Phase I study of the proteasome inhibitor bortezomib and pegylated and liposomal doxorubicin in patients with refractory hematologic malignancies. Proc Am Soc Clin Oncol 2003;22:200.
42. Barlogie B, Shaughnessy J, Tricot G, Jacobson J, Zangari M, Anaissie E, et al. Treatment of multiple myeloma. Blood 2004;103:20-32.
43. Yang H, Vescio R, Adams J, Schenkein D, Berenson J. A phase I/II study of combination treatment with bortezomib and melphalan (Vc + M) in patients with relapsed or refractory multiple myeloma (MM). Proc Am Soc Clin Oncol 2003;22:582.